Determined.
Passionate.
Driving change.

For those you care for

Focusing on the development of new drugs for the treatment of inflammatory diseases

Our mission

Temisis is a therapeutic company focusing on the development of small-molecule assets for the treatment of unmet needs in pathologies possessing a strong inflammatory component.

 

Temisis is committed to developing small therapeutic molecules to fulfil unmet needs in pathologies involving IL-17/23 axis of inflammation.

Upcoming events

08junAll Day11BIO 2020SAN DIEGO, USA

News

Meet us on the Bio International Convention
in San Diego on June 8–11, 2020

Technology

Our main asset in dermatology, TEM1657, is a brand-new small molecule that shows great efficacy, orally and topically, at pre-clinical stage to remit psoriasis symptoms but without the common side effects that are associated with current treatments.

1

Rapid efficacy

Symptoms are significantly reduced after the first application of TEM1657.

2

Complete remission of psoriasis symptoms

No erythema – Regulated desquamation – Normal skin thickness.

3

Good safety profile

No skin thinning (unlike corticosteroids), no observed side effect on animals in toxicity tests.

icon-dataroom

Dataroom

Temisis is sharing latest non-confidential data about the development of TEM1657 with interested partners and potential investors.

Contact us

19 av de la Forêt de Haye,
54500 Vandœuvre-lès-Nancy
France
Tel.: +33 (0) 383 940 342
contact@temisis.com
www.temisis.com

icon-contact
X